Laboratorios RichmondC.I.F Valuation
Is RICHD undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of RICHD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate RICHD's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate RICHD's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for RICHD?
Key metric: As RICHD is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is RICHD's PE Ratio? | |
|---|---|
| PE Ratio | 8.7x |
| Earnings | AR$17.17b |
| Market Cap | AR$149.39b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 7.4x |
| Enterprise Value/EBITDA | 22.2x |
| PEG Ratio | n/a |
Price to Earnings Ratio vs Peers
How does RICHD's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 8.8x | ||
ROSE Instituto Rosenbusch | 4.7x | n/a | AR$4.7b |
A096760 JW Holdings | 3.1x | n/a | ₩212.2b |
531633 Lincoln Pharmaceuticals | 13x | n/a | ₹12.6b |
KOTRA Kotra Industries Berhad | 14.3x | 8.1% | RM 639.2m |
RICHD Laboratorios RichmondC.I.F | 8.7x | n/a | US$149.4b |
Price-To-Earnings vs Peers: RICHD is good value based on its Price-To-Earnings Ratio (8.7x) compared to the peer average (8.7x).
Price to Earnings Ratio vs Industry
How does RICHD's PE Ratio compare vs other companies in the Global Pharmaceuticals Industry?
| 26 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 26 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: RICHD is good value based on its Price-To-Earnings Ratio (8.7x) compared to the Global Pharmaceuticals industry average (22.6x).
Price to Earnings Ratio vs Fair Ratio
What is RICHD's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 8.7x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate RICHD's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Merck
US$255.9b
Operates as a healthcare company worldwide.
MRKD
US$21.40
7D
1.9%
1Y
7.3%
Novartis
CHF 183.8b
Engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally.
NVSD
CHF 28.40
7D
0%
1Y
n/a
GSK
UK£54.6b
Engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally.
GSKD
UK£8.85
7D
1.1%
1Y
-0.6%